ePrints

The development of PARP inhibitors in ovarian cancer: from bench to bedside

Lookup NU author(s): Dr Yvette DrewORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.

Publication metadata

Author(s): Drew Y

Publication type: Review

Publication status: Published

Journal: British Journal of Cancer

Year: 2015

Volume: 113

Pages: S3-S9

Online publication date: 15/12/2015

Acceptance date: 01/01/1900

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: NATURE PUBLISHING GROUP

URL: http://dx.doi.org/10.1038/bjc.2015.394

DOI: 10.1038/bjc.2015.394

Share